Department of Neurology, Benedictus Krankenhaus Tutzing & Feldafing, Abteilung für Neurologie, Dr,-Appelhans-Weg 6, Feldafing, 82360, Germany.
BMC Neurol. 2012 Sep 24;12:102. doi: 10.1186/1471-2377-12-102.
Patients in neurologic in-patient rehabilitation are at risk of cardio- and cerebrovascular events. Microalbuminuria (MAU) is frequent and an important risk predictor but has not been validated in in-patient rehabilitation. We therefore aimed to examine MAU as an indicator of risk and predictor of vascular events in a prospective study.
The INSIGHT (INvestigation of patients with ischemic Stroke In neuroloGic reHabiliTation) registry is the first to provide large scale data on 1,167 patients with acute stroke (< 3 months) that survived the initial phase of high risk and were undergoing neurologic in-patient rehabilitation. MAU was determined by dipstick-testing and correlated to baseline clinical variables (stroke-origin, functional impairment, co-morbidity, ankle-brachial-index, intima-media-thickeness) as well as vascular events after one year of follow-up. Comparisons were made with the χ2 or Mann-Whitney-U Test. Relative risks (RR) with 95% confidence intervals (CI) were estimated using log-binominal models. To evaluate the association between MAU and new vascular events as well as mortality, we calculated hazard ratios (HR) using Cox proportional hazard regression.
A substantial proportion of patients was MAU positive at baseline (33.1%). Upon univariate analysis these patients were about 4 years older (69 vs. 65 years; p < 0.0001), had a slightly higher body mass index (27.8 vs. 27.1 kg/m2; p = 0.03) and increased waist circumference (79.5 vs. 50.4% for women [p < 0.0001] and 46.8 vs. 43.2% for men [p = 0.04]) and twice as often had diabetes mellitus (41.8 vs. 20.1%; p < 0.0001). Patients with MAU had a similar NIH stroke scale score (median 3 vs. 3; p = 0.379) but had lower values on the Barthel Index (median 75 vs. 90; p < 0.001). They had higher rates of atrial fibrillation (RR 1.38; 95% CI 1.09-1.75), coronary artery disease (RR 1.54; 95% CI 1.18-2.00), heart failure (RR 1.70; 95% CI 1.10-2.60) symptomatic peripheral artery disease (RR 2.30; 95% CI 1.40-3.80) and atherosclerotic stroke etiology (53.7 vs. 35.4%; p < 0.0001). MAU was associated with an increased intima-media-thickness, decreased ankle-brachial-index and polyvascular disease (RR 1.56; 95%CI 1.31-1.99). The event rate after a median follow-up of 13 months was 6.7% for fatal or nonfatal stroke, 4.7% for death, and 10.9% for combined vascular events (stroke, MI, vascular death). The presence of MAU was predictive for vascular events during the following year (HR for total mortality 2.2; 95% CI 1.3-3.7; HR for cardiovascular events 2.3; 95% 1.2 - 4.4).
INSIGHT demonstrated a significant association between MAU and polyvascular disease and further supports previous findings that MAU predicts cardio-/cerebrovascular events in patients recovering from ischemic stroke. This biomarker may also be used in patients during neurologic in-patient rehabilitation, opening a window of opportunity for early intervention in this patient group at increased risk for recurrent events.
神经内科住院患者存在心脑血管事件风险。微量白蛋白尿(MAU)较为常见,是一个重要的风险预测指标,但尚未在住院康复患者中得到验证。因此,我们旨在前瞻性研究中,检测 MAU 作为风险指标和血管事件预测因子。
INSIGHT(缺血性脑卒中患者神经康复的调查)登记研究首次提供了 1167 例急性脑卒中(<3 个月)患者的大规模数据,这些患者在高危初始阶段存活下来,正在接受神经内科住院康复治疗。MAU 通过试纸检测确定,并与基线临床变量(脑卒中起源、功能障碍、合并症、踝肱指数、内中膜厚度)以及一年随访后的血管事件相关联。采用 χ2 或曼-惠特尼 U 检验进行比较。使用对数二项式模型估计相对风险(RR)及其 95%置信区间(CI)。为了评估 MAU 与新发血管事件和死亡率之间的关联,我们使用 Cox 比例风险回归计算了危险比(HR)。
相当一部分患者在基线时 MAU 阳性(33.1%)。在单变量分析中,这些患者的年龄大 4 岁(69 岁与 65 岁;p<0.0001),体重指数略高(27.8 千克/平方米与 27.1 千克/平方米;p=0.03),腰围较大(女性分别为 79.5%和 50.4%[p<0.0001],男性分别为 46.8%和 43.2%[p=0.04]),且糖尿病的发生率是两倍(41.8%与 20.1%;p<0.0001)。MAU 患者的 NIH 脑卒中量表评分相似(中位数 3 分与 3 分;p=0.379),但 Barthel 指数较低(中位数 75 分与 90 分;p<0.001)。他们的心房颤动(RR 1.38;95%CI 1.09-1.75)、冠状动脉疾病(RR 1.54;95%CI 1.18-2.00)、心力衰竭(RR 1.70;95%CI 1.10-2.60)、有症状外周动脉疾病(RR 2.30;95%CI 1.40-3.80)和动脉粥样硬化性脑卒中病因(53.7%与 35.4%;p<0.0001)的发生率较高。MAU 与内膜中层厚度增加、踝肱指数降低和多血管疾病相关(RR 1.56;95%CI 1.31-1.99)。中位数为 13 个月的随访期间,总死亡率为 6.7%(致命或非致命性脑卒中)、4.7%(死亡)和 10.9%(联合血管事件[脑卒中、心肌梗死、血管性死亡])。MAU 的存在与下一年的血管事件相关(总死亡率的 HR 为 2.2;95%CI 1.3-3.7;心血管事件的 HR 为 2.3;95%CI 1.2-4.4)。
INSIGHT 显示 MAU 与多血管疾病之间存在显著关联,并进一步支持先前的发现,即 MAU 可预测缺血性脑卒中后患者的心/脑血管事件。该生物标志物也可用于神经内科住院康复患者,为该高复发风险人群提供了早期干预的机会。